SEC Form 4 · accession 0001562180-16-001664
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Alan Huizenga
Officer — Controller and PAO
Period of report
Feb 12, 2016
Accepted (ET)
Feb 17, 2016 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2016 | M | 1,000 | $21.00 | A | 4,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $21.00 | Feb 12, 2016 | M | 1,000 | D | — | Jan 29, 2024 | Common Stock | 1,000 | 24,403 | D |
Explanation of responses
- F11/4 of the shares underlying the option vested on January 27, 2015 and then 1/48th of the underlying shares will vest monthly thereafter, provided the Reporting Person has not terminated services with the Issuer.